Advanced

Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues

Sundkvist, G M; Björk, Thomas LU ; Kjellström, H and Lilja, B (1996) In Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00 30(1). p.29-32
Abstract
In 14 men with prostatic carcinoma, quantitative scintigraphy of the vertebrae from Th10 to L5 was performed before and 2 weeks and 2 and 6 months after start of treatment with luteinizing hormone-releasing hormone (LH-RH) analogues. Serum prostate-specific antigen (PSA) was also determined. The patients with normal bone scintigram showed no change in gamma camera count rate during the study, but fall in PSA values. The patients with abnormal bone scintigram responded to treatment with flare phenomenon, with increased count rate at 2 weeks, followed by fall to pretreatment level at 2 months. PSA showed decrease as early as 2 weeks after the start of treatment. Bone scintigraphy was found to be useful before therapy, especially in patients... (More)
In 14 men with prostatic carcinoma, quantitative scintigraphy of the vertebrae from Th10 to L5 was performed before and 2 weeks and 2 and 6 months after start of treatment with luteinizing hormone-releasing hormone (LH-RH) analogues. Serum prostate-specific antigen (PSA) was also determined. The patients with normal bone scintigram showed no change in gamma camera count rate during the study, but fall in PSA values. The patients with abnormal bone scintigram responded to treatment with flare phenomenon, with increased count rate at 2 weeks, followed by fall to pretreatment level at 2 months. PSA showed decrease as early as 2 weeks after the start of treatment. Bone scintigraphy was found to be useful before therapy, especially in patients with elevated PSA levels, and after 2 months, when the flare phenomenon had subsided. Serial measurement of PSA provided a guide to disease activity. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00
volume
30
issue
1
pages
29 - 32
publisher
Taylor & Francis
external identifiers
  • pmid:8727862
  • scopus:0029666398
ISSN
0036-5599
language
English
LU publication?
yes
id
2e2b9b5b-0e1d-47d8-aa9f-24c81155c289 (old id 1110177)
date added to LUP
2008-07-30 08:57:59
date last changed
2017-01-01 06:53:44
@article{2e2b9b5b-0e1d-47d8-aa9f-24c81155c289,
  abstract     = {In 14 men with prostatic carcinoma, quantitative scintigraphy of the vertebrae from Th10 to L5 was performed before and 2 weeks and 2 and 6 months after start of treatment with luteinizing hormone-releasing hormone (LH-RH) analogues. Serum prostate-specific antigen (PSA) was also determined. The patients with normal bone scintigram showed no change in gamma camera count rate during the study, but fall in PSA values. The patients with abnormal bone scintigram responded to treatment with flare phenomenon, with increased count rate at 2 weeks, followed by fall to pretreatment level at 2 months. PSA showed decrease as early as 2 weeks after the start of treatment. Bone scintigraphy was found to be useful before therapy, especially in patients with elevated PSA levels, and after 2 months, when the flare phenomenon had subsided. Serial measurement of PSA provided a guide to disease activity.},
  author       = {Sundkvist, G M and Björk, Thomas and Kjellström, H and Lilja, B},
  issn         = {0036-5599},
  language     = {eng},
  number       = {1},
  pages        = {29--32},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00},
  title        = {Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues},
  volume       = {30},
  year         = {1996},
}